NASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis $37.66 +0.30 (+0.80%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$37.64 -0.02 (-0.07%) As of 09/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immunovant Stock (NASDAQ:IMVT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunovant alerts:Sign Up Key Stats Today's Range$37.00▼$38.0350-Day Range$37.36▼$44.9652-Week Range$14.58▼$45.42Volume1.11 million shsAverage Volume1.11 million shsMarket Capitalization$7.78 billionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingModerate Buy Company Overview Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing therapies for patients with immune-mediated diseases. The company focuses on conditions in which disease-causing antibodies, or immunoglobulin G (IgG), play a central role, including autoimmune and inflammatory disorders. Immunovant’s lead product candidate is batoclimab, an investigational fully human monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting FcRn, batoclimab is intended to reduce circulating IgG antibodies that can contribute to autoimmune disease. The company has evaluated the therapy in conditions including thyroid eye disease, myasthenia gravis and Graves’ disease. Immunovant is also advancing IMVT-1402, an investigational next-generation FcRn inhibitor intended to support the treatment of autoimmune disorders. Immunovant was established as a subsidiary of Roivant Sciences and operates as part of Roivant’s broader biotechnology platform. Its programs are being developed for potential use in the United States and other international markets through clinical research and regulatory activities. The company is led by Chief Executive Officer Pete Salzmann, M.D., and is headquartered in New York.AI Generated. May Contain Errors. Read More Immunovant Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreIMVT MarketRank™: Immunovant scored higher than 48% of companies evaluated by MarketBeat, and ranked 550th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingImmunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on no strong buy ratings, 7 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialImmunovant has a consensus price target of $44.00, representing about 16.8% upside from its current price of $37.66.Amount of Analyst CoverageImmunovant has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunovant's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($2.96) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -13.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -13.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 8.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.79% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 14.05, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently decreased by 7.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.37 News SentimentImmunovant has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immunovant this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows3 people have added Immunovant to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,785,493.00 in company stock.Percentage Held by Insiders1.90% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMVT Stock News HeadlinesImmunovant, Inc. (NASDAQ:IMVT) Receives $44.00 Average Price Target from BrokeragesSeptember 10, 2026 | americanbankingnews.comImmunovant Shareholders Back Board, Auditor and Executive PaySeptember 3, 2026 | tipranks.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)Immunovant (NASDAQ:IMVT) Director Sells 1,500 SharesAugust 29, 2026 | insidertrades.comImmunovant's Risk/Reward Profile Balanced After Recent Rally, UBS SaysAugust 24, 2026 | finance.yahoo.comKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmAugust 19, 2026 | prnewswire.comImmunovant (IMVT) Receives a Buy from OppenheimerAugust 13, 2026 | theglobeandmail.comImmunovant (IMVT) Q1 2027 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comSee More Headlines IMVT Stock Analysis - Frequently Asked Questions How have IMVT shares performed this year? Immunovant's stock was trading at $25.42 on January 1st, 2026. Since then, IMVT stock has increased by 48.2% and is now trading at $37.66. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.12. The firm earned $7.10 million during the quarter, compared to analyst estimates of $7.10 million. Read the conference call transcript. Who are Immunovant's major shareholders? Top institutional investors of Immunovant include BlackRock Inc. (3.48%), California State Teachers Retirement System (1.71%), Two Seas Capital LP (1.52%) and ADAR1 Capital Management LLC (1.13%). Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Eva Renee Barnett, William L Macias, Mark S Levine, Eric Venker, Tiago Girao, Melanie Gloria, Michael Geffner, Jay S Stout, Tuyl Christopher Van, Douglas J Hughes, Atul Pande, Andrew J Fromkin and Robert Graham Susman. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today9/14/2026Next Earnings (Estimated)11/09/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IMVT's financial health is in the Green zone, according to TradeSmith. IMVT has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMVT CIK1764013 Webwww.immunovant.com Phone(917) 410-3120FaxN/AEmployees315Year Founded2018Price Target and Rating Average Price Target for Immunovant$44.00 High Price Target$62.00 Low Price Target$28.00 Potential Upside/Downside+16.8%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$505.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.59% Return on Assets-62.49% Debt Debt-to-Equity RatioN/A Current Ratio7.27 Quick Ratio7.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book8.99Miscellaneous Outstanding Shares206,553,000Free Float202,628,000Market Cap$7.78 billion OptionableOptionable Beta0.81 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:IMVT) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
